#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Aging-associated disabilities are generated by an accumulation of randomly occurring molecular damages during life time , which affect the organism at multiple levels such as metabolism , immune response , repair , and regeneration as well as altered inter- and intracellular communication .
3-1	17-33	Aging-associated	abstract[3]	new[3]	_	_
3-2	34-46	disabilities	abstract[3]	new[3]	_	_
3-3	47-50	are	_	_	_	_
3-4	51-60	generated	_	_	_	_
3-5	61-63	by	_	_	_	_
3-6	64-66	an	abstract[4]	new[4]	coref	5-6[28_4]
3-7	67-79	accumulation	abstract[4]	new[4]	_	_
3-8	80-82	of	_	_	_	_
3-9	83-91	randomly	_	_	_	_
3-10	92-101	occurring	_	_	_	_
3-11	102-111	molecular	abstract[5]	new[5]	_	_
3-12	112-119	damages	abstract[5]	new[5]	_	_
3-13	120-126	during	_	_	_	_
3-14	127-131	life	abstract|abstract[7]	new|new[7]	_	_
3-15	132-136	time	abstract[7]	new[7]	_	_
3-16	137-138	,	_	_	_	_
3-17	139-144	which	_	_	_	_
3-18	145-151	affect	_	_	_	_
3-19	152-155	the	abstract[8]	new[8]	_	_
3-20	156-164	organism	abstract[8]	new[8]	_	_
3-21	165-167	at	abstract[8]	new[8]	_	_
3-22	168-176	multiple	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-23	177-183	levels	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-24	184-188	such	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-25	189-191	as	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-26	192-202	metabolism	abstract[8]|abstract[9]|abstract	new[8]|new[9]|new	coref	23-22[183_0]
3-27	203-204	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-28	205-211	immune	abstract[8]|abstract[9]|abstract|abstract[12]	new[8]|new[9]|new|new[12]	coref|coref|coref|coref	13-8[83_12]|16-17|13-8[83_12]|16-17
3-29	212-220	response	abstract[8]|abstract[9]|abstract[12]	new[8]|new[9]|new[12]	_	_
3-30	221-222	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-31	223-229	repair	abstract[8]|abstract[9]|abstract	new[8]|new[9]|new	_	_
3-32	230-231	,	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-33	232-235	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-34	236-248	regeneration	abstract[8]|abstract[9]|event	new[8]|new[9]|new	_	_
3-35	249-251	as	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-36	252-256	well	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-37	257-259	as	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-38	260-267	altered	abstract[8]|abstract[9]|abstract[15]	new[8]|new[9]|new[15]	_	_
3-39	268-274	inter-	abstract[8]|abstract[9]|abstract[15]	new[8]|new[9]|new[15]	_	_
3-40	275-278	and	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-41	279-292	intracellular	abstract[8]|abstract[9]|abstract[16]	new[8]|new[9]|new[16]	_	_
3-42	293-306	communication	abstract[8]|abstract[9]|abstract[16]	new[8]|new[9]|new[16]	_	_
3-43	307-308	.	_	_	_	_

#Text=Typical alterations detectable in aged tissues are increased concentrations of reactive oxygen species ( ROS ) and concomitant increased DNA-damage , lipid and protein oxidation .
4-1	309-316	Typical	abstract[17]	new[17]	coref	4-8[19_17]
4-2	317-328	alterations	abstract[17]	new[17]	_	_
4-3	329-339	detectable	_	_	_	_
4-4	340-342	in	_	_	_	_
4-5	343-347	aged	object[18]	new[18]	coref	12-11[0_18]
4-6	348-355	tissues	object[18]	new[18]	_	_
4-7	356-359	are	_	_	_	_
4-8	360-369	increased	abstract[19]	giv[19]	_	_
4-9	370-384	concentrations	abstract[19]	giv[19]	_	_
4-10	385-387	of	abstract[19]	giv[19]	_	_
4-11	388-396	reactive	abstract[19]|abstract[21]	giv[19]|new[21]	_	_
4-12	397-403	oxygen	abstract[19]|substance|abstract[21]	giv[19]|new|new[21]	_	_
4-13	404-411	species	abstract[19]|abstract[21]	giv[19]|new[21]	_	_
4-14	412-413	(	_	_	_	_
4-15	414-417	ROS	substance	new	_	_
4-16	418-419	)	_	_	_	_
4-17	420-423	and	_	_	_	_
4-18	424-435	concomitant	substance[23]	new[23]	_	_
4-19	436-445	increased	substance[23]	new[23]	_	_
4-20	446-456	DNA-damage	substance[23]	new[23]	_	_
4-21	457-458	,	_	_	_	_
4-22	459-464	lipid	substance	new	coref	14-10
4-23	465-468	and	_	_	_	_
4-24	469-476	protein	substance|abstract[26]	new|new[26]	ana|coref|ana|coref	5-2[0_26]|5-9|5-2[0_26]|5-9
4-25	477-486	oxidation	abstract[26]	new[26]	_	_
4-26	487-488	.	_	_	_	_

#Text=Often this is accompanied by accumulation of insoluble protein aggregates ( lipofuscin ) at least partially as a consequence of impaired proteasome function .
5-1	489-494	Often	_	_	_	_
5-2	495-499	this	abstract	giv	coref	9-12[58_0]
5-3	500-502	is	_	_	_	_
5-4	503-514	accompanied	_	_	_	_
5-5	515-517	by	_	_	_	_
5-6	518-530	accumulation	abstract[28]	giv[28]	_	_
5-7	531-533	of	abstract[28]	giv[28]	_	_
5-8	534-543	insoluble	abstract[28]|abstract[30]	giv[28]|new[30]	coref	14-29[105_30]
5-9	544-551	protein	abstract[28]|substance|abstract[30]	giv[28]|giv|new[30]	coref	14-30
5-10	552-562	aggregates	abstract[28]|abstract[30]	giv[28]|new[30]	_	_
5-11	563-564	(	_	_	_	_
5-12	565-575	lipofuscin	person	new	_	_
5-13	576-577	)	_	_	_	_
5-14	578-580	at	_	_	_	_
5-15	581-586	least	_	_	_	_
5-16	587-596	partially	_	_	_	_
5-17	597-599	as	_	_	_	_
5-18	600-601	a	_	_	_	_
5-19	602-613	consequence	_	_	_	_
5-20	614-616	of	_	_	_	_
5-21	617-625	impaired	abstract[33]	new[33]	coref	6-13[36_33]
5-22	626-636	proteasome	object|abstract[33]	new|new[33]	_	_
5-23	637-645	function	abstract[33]	new[33]	_	_
5-24	646-647	.	_	_	_	_

#Text=In addition , glycation was reported to contribute to limited degradation and function of proteins .
6-1	648-650	In	_	_	_	_
6-2	651-659	addition	_	_	_	_
6-3	660-661	,	_	_	_	_
6-4	662-671	glycation	substance	new	coref	7-1
6-5	672-675	was	_	_	_	_
6-6	676-684	reported	_	_	_	_
6-7	685-687	to	_	_	_	_
6-8	688-698	contribute	_	_	_	_
6-9	699-701	to	_	_	_	_
6-10	702-709	limited	abstract[35]	new[35]	_	_
6-11	710-721	degradation	abstract[35]	new[35]	_	_
6-12	722-725	and	_	_	_	_
6-13	726-734	function	abstract[36]	giv[36]	_	_
6-14	735-737	of	abstract[36]	giv[36]	_	_
6-15	738-746	proteins	abstract[36]|substance	giv[36]|new	coref	14-25
6-16	747-748	.	_	_	_	_

#Text=Glycation represents an important posttranslational modification that significantly increases during aging and results in the formation of advanced glycation end products ( AGEs ) .
7-1	749-758	Glycation	substance	giv	coref	7-19
7-2	759-769	represents	_	_	_	_
7-3	770-772	an	abstract[39]	new[39]	coref	18-4[135_39]
7-4	773-782	important	abstract[39]	new[39]	_	_
7-5	783-800	posttranslational	abstract[39]	new[39]	_	_
7-6	801-813	modification	abstract[39]	new[39]	_	_
7-7	814-818	that	_	_	_	_
7-8	819-832	significantly	_	_	_	_
7-9	833-842	increases	_	_	_	_
7-10	843-849	during	_	_	_	_
7-11	850-855	aging	abstract	new	coref	21-16
7-12	856-859	and	_	_	_	_
7-13	860-867	results	abstract	new	_	_
7-14	868-870	in	_	_	_	_
7-15	871-874	the	abstract[42]	new[42]	_	_
7-16	875-884	formation	abstract[42]	new[42]	_	_
7-17	885-887	of	abstract[42]	new[42]	_	_
7-18	888-896	advanced	abstract[42]|object[45]	new[42]|new[45]	appos	7-23[0_45]
7-19	897-906	glycation	abstract[42]|abstract|object[45]	new[42]|giv|new[45]	coref	11-23
7-20	907-910	end	abstract[42]|abstract|object[45]	new[42]|new|new[45]	coref	18-17
7-21	911-919	products	abstract[42]|object[45]	new[42]|new[45]	_	_
7-22	920-921	(	_	_	_	_
7-23	922-926	AGEs	object	giv	coref	8-1
7-24	927-928	)	_	_	_	_
7-25	929-930	.	_	_	_	_

#Text=AGEs are generated by an initial non-enzymatic reaction of amino groups with reactive carbonyl groups of monosaccharides known as the Maillard reaction , thereby forming Schiff-base adducts .
8-1	931-935	AGEs	object	giv	coref	9-7[57_0]
8-2	936-939	are	_	_	_	_
8-3	940-949	generated	_	_	_	_
8-4	950-952	by	_	_	_	_
8-5	953-955	an	event[48]	new[48]	_	_
8-6	956-963	initial	event[48]	new[48]	_	_
8-7	964-977	non-enzymatic	event[48]	new[48]	_	_
8-8	978-986	reaction	event[48]	new[48]	_	_
8-9	987-989	of	event[48]	new[48]	_	_
8-10	990-995	amino	event[48]|person[49]	new[48]|new[49]	_	_
8-11	996-1002	groups	event[48]|person[49]	new[48]|new[49]	_	_
8-12	1003-1007	with	event[48]|person[49]	new[48]|new[49]	_	_
8-13	1008-1016	reactive	event[48]|person[49]|person[51]	new[48]|new[49]|new[51]	_	_
8-14	1017-1025	carbonyl	event[48]|person[49]|organization|person[51]	new[48]|new[49]|new|new[51]	_	_
8-15	1026-1032	groups	event[48]|person[49]|person[51]	new[48]|new[49]|new[51]	_	_
8-16	1033-1035	of	event[48]|person[49]|person[51]	new[48]|new[49]|new[51]	_	_
8-17	1036-1051	monosaccharides	event[48]|person[49]|person[51]|substance	new[48]|new[49]|new[51]|new	_	_
8-18	1052-1057	known	_	_	_	_
8-19	1058-1060	as	_	_	_	_
8-20	1061-1064	the	_	_	_	_
8-21	1065-1073	Maillard	person	new	_	_
8-22	1074-1082	reaction	_	_	_	_
8-23	1083-1084	,	_	_	_	_
8-24	1085-1092	thereby	_	_	_	_
8-25	1093-1100	forming	_	_	_	_
8-26	1101-1112	Schiff-base	abstract[54]	new[54]	coref	9-1[55_54]
8-27	1113-1120	adducts	abstract[54]	new[54]	_	_
8-28	1121-1122	.	_	_	_	_

#Text=These adducts are subsequently rearranged to so-called Amadori products which undergo further oxidation and dehydration reactions leading to a large group of heterogeneous products .
9-1	1123-1128	These	abstract[55]	giv[55]	coref	10-10[0_55]
9-2	1129-1136	adducts	abstract[55]	giv[55]	_	_
9-3	1137-1140	are	_	_	_	_
9-4	1141-1153	subsequently	_	_	_	_
9-5	1154-1164	rearranged	_	_	_	_
9-6	1165-1167	to	_	_	_	_
9-7	1168-1177	so-called	object[57]	giv[57]	coref	9-23[62_57]
9-8	1178-1185	Amadori	person|object[57]	new|giv[57]	coref	10-7
9-9	1186-1194	products	object[57]	giv[57]	_	_
9-10	1195-1200	which	_	_	_	_
9-11	1201-1208	undergo	_	_	_	_
9-12	1209-1216	further	abstract[58]	giv[58]	_	_
9-13	1217-1226	oxidation	abstract[58]	giv[58]	_	_
9-14	1227-1230	and	_	_	_	_
9-15	1231-1242	dehydration	abstract|event[60]	new|new[60]	_	_
9-16	1243-1252	reactions	event[60]	new[60]	_	_
9-17	1253-1260	leading	_	_	_	_
9-18	1261-1263	to	_	_	_	_
9-19	1264-1265	a	abstract[61]	new[61]	_	_
9-20	1266-1271	large	abstract[61]	new[61]	_	_
9-21	1272-1277	group	abstract[61]	new[61]	_	_
9-22	1278-1280	of	abstract[61]	new[61]	_	_
9-23	1281-1294	heterogeneous	abstract[61]|object[62]	new[61]|giv[62]	coref	10-6[65_62]
9-24	1295-1303	products	abstract[61]|object[62]	new[61]|giv[62]	_	_
9-25	1304-1305	.	_	_	_	_

#Text=Up to the stage of the Amadori products , adducts are basically reversible .
10-1	1306-1308	Up	_	_	_	_
10-2	1309-1311	to	_	_	_	_
10-3	1312-1315	the	time[63]	new[63]	_	_
10-4	1316-1321	stage	time[63]	new[63]	_	_
10-5	1322-1324	of	time[63]	new[63]	_	_
10-6	1325-1328	the	time[63]|object[65]	new[63]|giv[65]	coref	12-1[75_65]
10-7	1329-1336	Amadori	time[63]|person|object[65]	new[63]|giv|giv[65]	_	_
10-8	1337-1345	products	time[63]|object[65]	new[63]|giv[65]	_	_
10-9	1346-1347	,	_	_	_	_
10-10	1348-1355	adducts	abstract	giv	_	_
10-11	1356-1359	are	_	_	_	_
10-12	1360-1369	basically	_	_	_	_
10-13	1370-1380	reversible	_	_	_	_
10-14	1381-1382	.	_	_	_	_

#Text=Preferentially lysine residues , but also other amino acids including arginine , histidine , tryptophan , or cysteine , are modified by glycation .
11-1	1383-1397	Preferentially	substance[68]	new[68]	_	_
11-2	1398-1404	lysine	abstract|substance[68]	new|new[68]	_	_
11-3	1405-1413	residues	substance[68]	new[68]	_	_
11-4	1414-1415	,	_	_	_	_
11-5	1416-1419	but	_	_	_	_
11-6	1420-1424	also	_	_	_	_
11-7	1425-1430	other	substance[69]	new[69]	_	_
11-8	1431-1436	amino	substance[69]	new[69]	_	_
11-9	1437-1442	acids	substance[69]	new[69]	_	_
11-10	1443-1452	including	substance[69]	new[69]	_	_
11-11	1453-1461	arginine	substance[69]|substance	new[69]|new	_	_
11-12	1462-1463	,	substance[69]	new[69]	_	_
11-13	1464-1473	histidine	substance[69]|substance	new[69]|new	_	_
11-14	1474-1475	,	substance[69]	new[69]	_	_
11-15	1476-1486	tryptophan	substance[69]|substance	new[69]|new	_	_
11-16	1487-1488	,	substance[69]	new[69]	_	_
11-17	1489-1491	or	substance[69]	new[69]	_	_
11-18	1492-1500	cysteine	substance[69]|substance	new[69]|new	_	_
11-19	1501-1502	,	_	_	_	_
11-20	1503-1506	are	_	_	_	_
11-21	1507-1515	modified	_	_	_	_
11-22	1516-1518	by	_	_	_	_
11-23	1519-1528	glycation	substance	giv	coref	16-8
11-24	1529-1530	.	_	_	_	_

#Text=The most prominent and well-known AGEs identified in cells and tissues are carboxymethyllysine ( CML ) , carboxyethyllysine ( CEL ) , pentosidine , and desoxyglucosone .
12-1	1531-1534	The	object[75]	giv[75]	coref	13-3[82_75]
12-2	1535-1539	most	object[75]	giv[75]	_	_
12-3	1540-1549	prominent	object[75]	giv[75]	_	_
12-4	1550-1553	and	object[75]	giv[75]	_	_
12-5	1554-1564	well-known	object[75]	giv[75]	_	_
12-6	1565-1569	AGEs	object[75]	giv[75]	_	_
12-7	1570-1580	identified	_	_	_	_
12-8	1581-1583	in	_	_	_	_
12-9	1584-1589	cells	object	new	_	_
12-10	1590-1593	and	_	_	_	_
12-11	1594-1601	tissues	object	giv	coref	15-20[112_0]
12-12	1602-1605	are	_	_	_	_
12-13	1606-1625	carboxymethyllysine	_	_	_	_
12-14	1626-1627	(	abstract[78]	new[78]	_	_
12-15	1628-1631	CML	abstract[78]	new[78]	_	_
12-16	1632-1633	)	abstract[78]	new[78]	_	_
12-17	1634-1635	,	abstract[78]	new[78]	_	_
12-18	1636-1654	carboxyethyllysine	abstract[78]	new[78]	_	_
12-19	1655-1656	(	abstract[78]	new[78]	_	_
12-20	1657-1660	CEL	abstract[78]|abstract	new[78]|new	_	_
12-21	1661-1662	)	abstract[78]	new[78]	_	_
12-22	1663-1664	,	abstract[78]	new[78]	_	_
12-23	1665-1676	pentosidine	abstract[78]|substance	new[78]|new	_	_
12-24	1677-1678	,	abstract[78]	new[78]	_	_
12-25	1679-1682	and	abstract[78]	new[78]	_	_
12-26	1683-1698	desoxyglucosone	abstract[78]|substance	new[78]|new	_	_
12-27	1699-1700	.	_	_	_	_

#Text=Physiologically , these AGEs are formed in response to so-called “ dicarbonyl stress ” as given under conditions of hyperglycemia or in the presence of highly reactive α-dicarbonyls ( α-DCs ) such as glyoxal ( GO ) , methylglyoxal ( MGO ) or 3-deoxyglucosone .
13-1	1701-1716	Physiologically	_	_	_	_
13-2	1717-1718	,	_	_	_	_
13-3	1719-1724	these	object[82]	giv[82]	coref	14-20[102_82]
13-4	1725-1729	AGEs	object[82]	giv[82]	_	_
13-5	1730-1733	are	_	_	_	_
13-6	1734-1740	formed	_	_	_	_
13-7	1741-1743	in	_	_	_	_
13-8	1744-1752	response	abstract[83]	giv[83]	_	_
13-9	1753-1755	to	abstract[83]	giv[83]	_	_
13-10	1756-1765	so-called	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
13-11	1766-1767	“	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
13-12	1768-1778	dicarbonyl	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
13-13	1779-1785	stress	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
13-14	1786-1787	”	abstract[83]|abstract[84]	giv[83]|new[84]	_	_
13-15	1788-1790	as	_	_	_	_
13-16	1791-1796	given	_	_	_	_
13-17	1797-1802	under	_	_	_	_
13-18	1803-1813	conditions	abstract[85]	new[85]	_	_
13-19	1814-1816	of	abstract[85]	new[85]	_	_
13-20	1817-1830	hyperglycemia	abstract[85]|abstract	new[85]|new	_	_
13-21	1831-1833	or	_	_	_	_
13-22	1834-1836	in	_	_	_	_
13-23	1837-1840	the	abstract[87]	new[87]	_	_
13-24	1841-1849	presence	abstract[87]	new[87]	_	_
13-25	1850-1852	of	abstract[87]	new[87]	_	_
13-26	1853-1859	highly	abstract[87]|substance[88]	new[87]|new[88]	appos	13-30[0_88]
13-27	1860-1868	reactive	abstract[87]|substance[88]	new[87]|new[88]	_	_
13-28	1869-1882	α-dicarbonyls	abstract[87]|substance[88]	new[87]|new[88]	_	_
13-29	1883-1884	(	_	_	_	_
13-30	1885-1890	α-DCs	substance	giv	coref	14-1[94_0]
13-31	1891-1892	)	_	_	_	_
13-32	1893-1897	such	_	_	_	_
13-33	1898-1900	as	_	_	_	_
13-34	1901-1908	glyoxal	substance	new	_	_
13-35	1909-1910	(	_	_	_	_
13-36	1911-1913	GO	_	_	_	_
13-37	1914-1915	)	_	_	_	_
13-38	1916-1917	,	_	_	_	_
13-39	1918-1931	methylglyoxal	substance	new	appos	13-41
13-40	1932-1933	(	_	_	_	_
13-41	1934-1937	MGO	substance	giv	_	_
13-42	1938-1939	)	_	_	_	_
13-43	1940-1942	or	_	_	_	_
13-44	1943-1959	3-deoxyglucosone	substance	new	_	_
13-45	1960-1961	.	_	_	_	_

#Text=These α-DCs are inevitable byproducts of anaerobic glycolysis and lipid peroxidation and in consequence , induce the formation of highly stable AGEs which crosslink proteins and lead to protease-resistant protein aggregates .
14-1	1962-1967	These	substance[94]	giv[94]	_	_
14-2	1968-1973	α-DCs	substance[94]	giv[94]	_	_
14-3	1974-1977	are	_	_	_	_
14-4	1978-1988	inevitable	_	_	_	_
14-5	1989-1999	byproducts	substance[95]	new[95]	_	_
14-6	2000-2002	of	substance[95]	new[95]	_	_
14-7	2003-2012	anaerobic	substance[95]|abstract|substance[97]	new[95]|new|new[97]	_	_
14-8	2013-2023	glycolysis	substance[95]|substance[97]	new[95]|new[97]	_	_
14-9	2024-2027	and	substance[95]	new[95]	_	_
14-10	2028-2033	lipid	substance[95]|person|substance[99]	new[95]|giv|new[99]	_	_
14-11	2034-2046	peroxidation	substance[95]|substance[99]	new[95]|new[99]	_	_
14-12	2047-2050	and	_	_	_	_
14-13	2051-2053	in	_	_	_	_
14-14	2054-2065	consequence	abstract	new	_	_
14-15	2066-2067	,	_	_	_	_
14-16	2068-2074	induce	_	_	_	_
14-17	2075-2078	the	event[101]	new[101]	_	_
14-18	2079-2088	formation	event[101]	new[101]	_	_
14-19	2089-2091	of	event[101]	new[101]	_	_
14-20	2092-2098	highly	event[101]|object[102]	new[101]|giv[102]	coref	16-10[0_102]
14-21	2099-2105	stable	event[101]|object[102]	new[101]|giv[102]	_	_
14-22	2106-2110	AGEs	event[101]|object[102]	new[101]|giv[102]	_	_
14-23	2111-2116	which	_	_	_	_
14-24	2117-2126	crosslink	_	_	_	_
14-25	2127-2135	proteins	substance	giv	coref	15-8[109_0]
14-26	2136-2139	and	_	_	_	_
14-27	2140-2144	lead	_	_	_	_
14-28	2145-2147	to	_	_	_	_
14-29	2148-2166	protease-resistant	abstract[105]	giv[105]	_	_
14-30	2167-2174	protein	substance|abstract[105]	giv|giv[105]	_	_
14-31	2175-2185	aggregates	abstract[105]	giv[105]	_	_
14-32	2186-2187	.	_	_	_	_

#Text=In this context , glycation-induced modifications of extracellular matrix proteins resulting in intermolecular crosslinks lead to increased stiffness of tissues and vessels and affect cell migration .
15-1	2188-2190	In	_	_	_	_
15-2	2191-2195	this	abstract[106]	new[106]	_	_
15-3	2196-2203	context	abstract[106]	new[106]	_	_
15-4	2204-2205	,	_	_	_	_
15-5	2206-2223	glycation-induced	abstract[107]	new[107]	coref	29-19[223_107]
15-6	2224-2237	modifications	abstract[107]	new[107]	_	_
15-7	2238-2240	of	abstract[107]	new[107]	_	_
15-8	2241-2254	extracellular	abstract[107]|substance[109]	new[107]|giv[109]	coref	29-14[222_109]
15-9	2255-2261	matrix	abstract[107]|abstract|substance[109]	new[107]|new|giv[109]	_	_
15-10	2262-2270	proteins	abstract[107]|substance[109]	new[107]|giv[109]	_	_
15-11	2271-2280	resulting	_	_	_	_
15-12	2281-2283	in	_	_	_	_
15-13	2284-2298	intermolecular	object[110]	new[110]	_	_
15-14	2299-2309	crosslinks	object[110]	new[110]	_	_
15-15	2310-2314	lead	_	_	_	_
15-16	2315-2317	to	_	_	_	_
15-17	2318-2327	increased	event[111]	new[111]	_	_
15-18	2328-2337	stiffness	event[111]	new[111]	_	_
15-19	2338-2340	of	event[111]	new[111]	_	_
15-20	2341-2348	tissues	event[111]|object[112]	new[111]|giv[112]	_	_
15-21	2349-2352	and	event[111]|object[112]	new[111]|giv[112]	_	_
15-22	2353-2360	vessels	event[111]|object[112]|object	new[111]|giv[112]|new	_	_
15-23	2361-2364	and	_	_	_	_
15-24	2365-2371	affect	_	_	_	_
15-25	2372-2376	cell	place|event[115]	new|new[115]	_	_
15-26	2377-2386	migration	event[115]	new[115]	_	_
15-27	2387-2388	.	_	_	_	_

#Text=Furthermore , there is clear evidence that glycation and AGEs lead to mitochondrial dysfunction and impaired immune responses .
16-1	2389-2400	Furthermore	_	_	_	_
16-2	2401-2402	,	_	_	_	_
16-3	2403-2408	there	_	_	_	_
16-4	2409-2411	is	_	_	_	_
16-5	2412-2417	clear	abstract[116]	new[116]	coref	23-5[176_116]
16-6	2418-2426	evidence	abstract[116]	new[116]	_	_
16-7	2427-2431	that	_	_	_	_
16-8	2432-2441	glycation	substance	giv	coref	17-1[123_0]
16-9	2442-2445	and	_	_	_	_
16-10	2446-2450	AGEs	object	giv	coref	18-15[140_0]
16-11	2451-2455	lead	_	_	_	_
16-12	2456-2458	to	_	_	_	_
16-13	2459-2472	mitochondrial	abstract|abstract[120]	new|new[120]	_	_
16-14	2473-2484	dysfunction	abstract[120]	new[120]	_	_
16-15	2485-2488	and	_	_	_	_
16-16	2489-2497	impaired	abstract[122]	new[122]	_	_
16-17	2498-2504	immune	abstract|abstract[122]	giv|new[122]	_	_
16-18	2505-2514	responses	abstract[122]	new[122]	_	_
16-19	2515-2516	.	_	_	_	_

#Text=Glycation of growth factors such as platelet-derived growth factor ( PDGF ) and insulin , as well as receptors such as nerve growth factor ( NGF)-receptor , were reported to affect signaling functions .
17-1	2517-2526	Glycation	substance[123]	giv[123]	coref	18-16[0_123]
17-2	2527-2529	of	substance[123]	giv[123]	_	_
17-3	2530-2536	growth	substance[123]|abstract[124]	giv[123]|new[124]	coref	26-32[203_124]
17-4	2537-2544	factors	substance[123]|abstract[124]	giv[123]|new[124]	_	_
17-5	2545-2549	such	substance[123]|abstract[124]	giv[123]|new[124]	_	_
17-6	2550-2552	as	substance[123]|abstract[124]	giv[123]|new[124]	_	_
17-7	2553-2569	platelet-derived	substance[123]|abstract[124]|abstract[126]	giv[123]|new[124]|new[126]	appos	17-11[0_126]
17-8	2570-2576	growth	substance[123]|abstract[124]|abstract|abstract[126]	giv[123]|new[124]|new|new[126]	coref	17-23
17-9	2577-2583	factor	substance[123]|abstract[124]|abstract[126]	giv[123]|new[124]|new[126]	_	_
17-10	2584-2585	(	_	_	_	_
17-11	2586-2590	PDGF	abstract	giv	coref	17-22[131_0]
17-12	2591-2592	)	_	_	_	_
17-13	2593-2596	and	_	_	_	_
17-14	2597-2604	insulin	substance	new	_	_
17-15	2605-2606	,	_	_	_	_
17-16	2607-2609	as	_	_	_	_
17-17	2610-2614	well	_	_	_	_
17-18	2615-2617	as	_	_	_	_
17-19	2618-2627	receptors	substance[129]	new[129]	_	_
17-20	2628-2632	such	substance[129]	new[129]	_	_
17-21	2633-2635	as	substance[129]	new[129]	_	_
17-22	2636-2641	nerve	substance[129]|abstract[131]	new[129]|giv[131]	coref	26-25[200_131]
17-23	2642-2648	growth	substance[129]|abstract|abstract[131]	new[129]|giv|giv[131]	_	_
17-24	2649-2655	factor	substance[129]|abstract[131]	new[129]|giv[131]	_	_
17-25	2656-2657	(	_	_	_	_
17-26	2658-2671	NGF)-receptor	person	new	_	_
17-27	2672-2673	,	_	_	_	_
17-28	2674-2678	were	_	_	_	_
17-29	2679-2687	reported	_	_	_	_
17-30	2688-2690	to	_	_	_	_
17-31	2691-2697	affect	_	_	_	_
17-32	2698-2707	signaling	abstract[133]	new[133]	_	_
17-33	2708-2717	functions	abstract[133]	new[133]	_	_
17-34	2718-2719	.	_	_	_	_

#Text=In addition , AGE modification itself can induce signaling mainly through the receptor for advanced glycation end products ( RAGE ) , a multi-ligand transmembrane receptor containing immunoglobulin domains .
18-1	2720-2722	In	_	_	_	_
18-2	2723-2731	addition	_	_	_	_
18-3	2732-2733	,	_	_	_	_
18-4	2734-2737	AGE	substance|abstract[135]	new|giv[135]	ana|ana	18-6[0_135]|18-6[0_135]
18-5	2738-2750	modification	abstract[135]	giv[135]	_	_
18-6	2751-2757	itself	abstract	giv	_	_
18-7	2758-2761	can	_	_	_	_
18-8	2762-2768	induce	_	_	_	_
18-9	2769-2778	signaling	_	_	_	_
18-10	2779-2785	mainly	_	_	_	_
18-11	2786-2793	through	_	_	_	_
18-12	2794-2797	the	substance[137]	new[137]	coref	18-23[142_137]
18-13	2798-2806	receptor	substance[137]	new[137]	_	_
18-14	2807-2810	for	substance[137]	new[137]	_	_
18-15	2811-2819	advanced	substance[137]|object[140]	new[137]|giv[140]	coref	20-6[158_140]
18-16	2820-2829	glycation	substance[137]|abstract|object[140]	new[137]|giv|giv[140]	coref	29-23
18-17	2830-2833	end	substance[137]|abstract|object[140]	new[137]|giv|giv[140]	_	_
18-18	2834-2842	products	substance[137]|object[140]	new[137]|giv[140]	_	_
18-19	2843-2844	(	_	_	_	_
18-20	2845-2849	RAGE	abstract	new	coref	20-8
18-21	2850-2851	)	_	_	_	_
18-22	2852-2853	,	_	_	_	_
18-23	2854-2855	a	substance[142]	giv[142]	_	_
18-24	2856-2868	multi-ligand	substance[142]	giv[142]	_	_
18-25	2869-2882	transmembrane	substance[142]	giv[142]	_	_
18-26	2883-2891	receptor	substance[142]	giv[142]	_	_
18-27	2892-2902	containing	_	_	_	_
18-28	2903-2917	immunoglobulin	person|abstract[144]	new|new[144]	_	_
18-29	2918-2925	domains	abstract[144]	new[144]	_	_
18-30	2926-2927	.	_	_	_	_

#Text=RAGE-induced signaling contributes to aging-related inflammation and metabolic diseases by modulation of multiple pathways including phosphoinositide 3-kinase ( PI3K ) , Erk1/2 and Wnt signaling .
19-1	2928-2940	RAGE-induced	abstract[145]	new[145]	coref	19-22[156_145]
19-2	2941-2950	signaling	abstract[145]	new[145]	_	_
19-3	2951-2962	contributes	_	_	_	_
19-4	2963-2965	to	_	_	_	_
19-5	2966-2979	aging-related	abstract[146]	new[146]	_	_
19-6	2980-2992	inflammation	abstract[146]	new[146]	_	_
19-7	2993-2996	and	_	_	_	_
19-8	2997-3006	metabolic	object|abstract[148]	new|new[148]	_	_
19-9	3007-3015	diseases	abstract[148]	new[148]	_	_
19-10	3016-3018	by	_	_	_	_
19-11	3019-3029	modulation	abstract[149]	new[149]	_	_
19-12	3030-3032	of	abstract[149]	new[149]	_	_
19-13	3033-3041	multiple	abstract[149]|place[150]	new[149]|new[150]	coref	22-12[171_150]
19-14	3042-3050	pathways	abstract[149]|place[150]	new[149]|new[150]	_	_
19-15	3051-3060	including	abstract[149]|place[150]	new[149]|new[150]	_	_
19-16	3061-3077	phosphoinositide	abstract[149]|place[150]|place|abstract[152]	new[149]|new[150]|new|new[152]	appos|appos	19-19[0_152]|19-19[0_152]
19-17	3078-3086	3-kinase	abstract[149]|place[150]|abstract[152]	new[149]|new[150]|new[152]	_	_
19-18	3087-3088	(	_	_	_	_
19-19	3089-3093	PI3K	abstract	giv	_	_
19-20	3094-3095	)	_	_	_	_
19-21	3096-3097	,	_	_	_	_
19-22	3098-3104	Erk1/2	abstract|abstract[156]	new|giv[156]	coref|coref	20-8[160_156]|20-8[160_156]
19-23	3105-3108	and	abstract[156]	giv[156]	_	_
19-24	3109-3112	Wnt	abstract|abstract[156]	new|giv[156]	coref	21-13
19-25	3113-3122	signaling	abstract[156]	giv[156]	_	_
19-26	3123-3124	.	_	_	_	_

#Text=However , the outcome of AGEs and RAGE signaling appears to be a double-edged sword with degenerative and protective effects .
20-1	3125-3132	However	_	_	_	_
20-2	3133-3134	,	_	_	_	_
20-3	3135-3138	the	abstract[157]	new[157]	_	_
20-4	3139-3146	outcome	abstract[157]	new[157]	_	_
20-5	3147-3149	of	abstract[157]	new[157]	_	_
20-6	3150-3154	AGEs	abstract[157]|object[158]	new[157]|giv[158]	_	_
20-7	3155-3158	and	abstract[157]|object[158]	new[157]|giv[158]	_	_
20-8	3159-3163	RAGE	abstract[157]|object[158]|abstract|abstract[160]	new[157]|giv[158]|giv|giv[160]	ana|ana	21-1[0_160]|21-1[0_160]
20-9	3164-3173	signaling	abstract[157]|object[158]|abstract[160]	new[157]|giv[158]|giv[160]	_	_
20-10	3174-3181	appears	_	_	_	_
20-11	3182-3184	to	_	_	_	_
20-12	3185-3187	be	_	_	_	_
20-13	3188-3189	a	abstract[161]	new[161]	_	_
20-14	3190-3202	double-edged	abstract[161]	new[161]	_	_
20-15	3203-3208	sword	abstract[161]	new[161]	_	_
20-16	3209-3213	with	abstract[161]	new[161]	_	_
20-17	3214-3226	degenerative	abstract[161]|abstract[162]	new[161]|new[162]	coref	30-17[232_162]
20-18	3227-3230	and	abstract[161]|abstract[162]	new[161]|new[162]	_	_
20-19	3231-3241	protective	abstract[161]|abstract[162]	new[161]|new[162]	_	_
20-20	3242-3249	effects	abstract[161]|abstract[162]	new[161]|new[162]	_	_
20-21	3250-3251	.	_	_	_	_

#Text=This also appears to be true in respect to the role of Wnt signaling in aging .
21-1	3252-3256	This	abstract	giv	coref	22-4
21-2	3257-3261	also	_	_	_	_
21-3	3262-3269	appears	_	_	_	_
21-4	3270-3272	to	_	_	_	_
21-5	3273-3275	be	_	_	_	_
21-6	3276-3280	true	_	_	_	_
21-7	3281-3283	in	_	_	_	_
21-8	3284-3291	respect	abstract[164]	new[164]	_	_
21-9	3292-3294	to	abstract[164]	new[164]	_	_
21-10	3295-3298	the	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-11	3299-3303	role	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-12	3304-3306	of	abstract[164]|abstract[165]	new[164]|new[165]	_	_
21-13	3307-3310	Wnt	abstract[164]|abstract[165]|abstract	new[164]|new[165]|giv	coref	23-12
21-14	3311-3320	signaling	_	_	_	_
21-15	3321-3323	in	_	_	_	_
21-16	3324-3329	aging	abstract	giv	_	_
21-17	3330-3331	.	_	_	_	_

#Text=The canonical Wnt/β-catenin signaling cascade acts as a pivotal regulator of developmental and pathogenesis pathways including cell stemness maintenance/differentiation , carcinogenesis , and aging-related phenotypes .
22-1	3332-3335	The	abstract[170]	new[170]	_	_
22-2	3336-3345	canonical	abstract[170]	new[170]	_	_
22-3	3346-3359	Wnt/β-catenin	abstract|abstract[170]	new|new[170]	_	_
22-4	3360-3369	signaling	abstract|abstract[170]	giv|new[170]	coref	24-5
22-5	3370-3377	cascade	abstract[170]	new[170]	_	_
22-6	3378-3382	acts	_	_	_	_
22-7	3383-3385	as	_	_	_	_
22-8	3386-3387	a	_	_	_	_
22-9	3388-3395	pivotal	_	_	_	_
22-10	3396-3405	regulator	_	_	_	_
22-11	3406-3408	of	_	_	_	_
22-12	3409-3422	developmental	place[171]	giv[171]	_	_
22-13	3423-3426	and	place[171]	giv[171]	_	_
22-14	3427-3439	pathogenesis	place[171]	giv[171]	_	_
22-15	3440-3448	pathways	place[171]	giv[171]	_	_
22-16	3449-3458	including	place[171]	giv[171]	_	_
22-17	3459-3463	cell	place[171]|abstract[173]	giv[171]|new[173]	_	_
22-18	3464-3472	stemness	place[171]|abstract|abstract[173]	giv[171]|new|new[173]	_	_
22-19	3473-3500	maintenance/differentiation	place[171]|abstract[173]	giv[171]|new[173]	_	_
22-20	3501-3502	,	place[171]	giv[171]	_	_
22-21	3503-3517	carcinogenesis	place[171]|abstract	giv[171]|new	_	_
22-22	3518-3519	,	place[171]	giv[171]	_	_
22-23	3520-3523	and	place[171]	giv[171]	_	_
22-24	3524-3537	aging-related	place[171]|abstract[175]	giv[171]|new[175]	_	_
22-25	3538-3548	phenotypes	place[171]|abstract[175]	giv[171]|new[175]	_	_
22-26	3549-3550	.	_	_	_	_

#Text=Moreover , there is clear evidence for a role of the Wnt pathway in mitochondrial respiratory capacity and metabolic homeostasis , especially of glucose metabolism .
23-1	3551-3559	Moreover	_	_	_	_
23-2	3560-3561	,	_	_	_	_
23-3	3562-3567	there	_	_	_	_
23-4	3568-3570	is	_	_	_	_
23-5	3571-3576	clear	abstract[176]	giv[176]	_	_
23-6	3577-3585	evidence	abstract[176]	giv[176]	_	_
23-7	3586-3589	for	abstract[176]	giv[176]	_	_
23-8	3590-3591	a	abstract[176]|abstract[177]	giv[176]|new[177]	_	_
23-9	3592-3596	role	abstract[176]|abstract[177]	giv[176]|new[177]	_	_
23-10	3597-3599	of	abstract[176]|abstract[177]	giv[176]|new[177]	_	_
23-11	3600-3603	the	abstract[176]|abstract[177]|place[179]	giv[176]|new[177]|new[179]	coref	24-2[186_179]
23-12	3604-3607	Wnt	abstract[176]|abstract[177]|abstract|place[179]	giv[176]|new[177]|giv|new[179]	coref	24-4
23-13	3608-3615	pathway	abstract[176]|abstract[177]|place[179]	giv[176]|new[177]|new[179]	_	_
23-14	3616-3618	in	abstract[176]|abstract[177]|place[179]	giv[176]|new[177]|new[179]	_	_
23-15	3619-3632	mitochondrial	abstract[176]|abstract[177]|place[179]|abstract[180]	giv[176]|new[177]|new[179]|new[180]	_	_
23-16	3633-3644	respiratory	abstract[176]|abstract[177]|place[179]|abstract[180]	giv[176]|new[177]|new[179]|new[180]	_	_
23-17	3645-3653	capacity	abstract[176]|abstract[177]|place[179]|abstract[180]	giv[176]|new[177]|new[179]|new[180]	_	_
23-18	3654-3657	and	abstract[176]|abstract[177]|place[179]	giv[176]|new[177]|new[179]	_	_
23-19	3658-3667	metabolic	abstract[176]|abstract[177]|place[179]|abstract[181]	giv[176]|new[177]|new[179]|new[181]	_	_
23-20	3668-3679	homeostasis	abstract[176]|abstract[177]|place[179]|abstract[181]	giv[176]|new[177]|new[179]|new[181]	_	_
23-21	3680-3681	,	abstract[176]|abstract[177]|place[179]|abstract[181]	giv[176]|new[177]|new[179]|new[181]	_	_
23-22	3682-3692	especially	abstract[176]|abstract[177]|place[179]|abstract[181]|abstract[183]	giv[176]|new[177]|new[179]|new[181]|giv[183]	_	_
23-23	3693-3695	of	abstract[176]|abstract[177]|place[179]|abstract[181]|abstract[183]	giv[176]|new[177]|new[179]|new[181]|giv[183]	_	_
23-24	3696-3703	glucose	abstract[176]|abstract[177]|place[179]|abstract[181]|substance|abstract[183]	giv[176]|new[177]|new[179]|new[181]|new|giv[183]	_	_
23-25	3704-3714	metabolism	abstract[176]|abstract[177]|place[179]|abstract[181]|abstract[183]	giv[176]|new[177]|new[179]|new[181]|giv[183]	_	_
23-26	3715-3716	.	_	_	_	_

#Text=Within the canonical Wnt signaling pathway , β-catenin is the central player .
24-1	3717-3723	Within	_	_	_	_
24-2	3724-3727	the	place[186]	giv[186]	coref	25-9[190_186]
24-3	3728-3737	canonical	place[186]	giv[186]	_	_
24-4	3738-3741	Wnt	abstract|place[186]	giv|giv[186]	coref	29-9
24-5	3742-3751	signaling	abstract|place[186]	giv|giv[186]	coref	29-27
24-6	3752-3759	pathway	place[186]	giv[186]	_	_
24-7	3760-3761	,	_	_	_	_
24-8	3762-3771	β-catenin	abstract	new	coref	24-10[188_0]
24-9	3772-3774	is	_	_	_	_
24-10	3775-3778	the	abstract[188]	giv[188]	coref	25-3[189_188]
24-11	3779-3786	central	abstract[188]	giv[188]	_	_
24-12	3787-3793	player	abstract[188]	giv[188]	_	_
24-13	3794-3795	.	_	_	_	_

#Text=Normally , excess β-catenin is rapidly degraded by the ubiquitin-proteasome pathway .
25-1	3796-3804	Normally	_	_	_	_
25-2	3805-3806	,	_	_	_	_
25-3	3807-3813	excess	abstract[189]	giv[189]	coref	26-10[0_189]
25-4	3814-3823	β-catenin	abstract[189]	giv[189]	_	_
25-5	3824-3826	is	_	_	_	_
25-6	3827-3834	rapidly	_	_	_	_
25-7	3835-3843	degraded	_	_	_	_
25-8	3844-3846	by	_	_	_	_
25-9	3847-3850	the	place[190]	giv[190]	coref	26-3[192_190]
25-10	3851-3871	ubiquitin-proteasome	place[190]	giv[190]	_	_
25-11	3872-3879	pathway	place[190]	giv[190]	_	_
25-12	3880-3881	.	_	_	_	_

#Text=Activation of the pathway leads to the stabilization of β-catenin and its accumulation within the cytosol and the nucleus , where it interacts with T-cell factor/lymphoid enhancer-binding factor ( TCF/LEF ) transcription factors and thereby regulates transcription of multiple target genes .
26-1	3882-3892	Activation	abstract[191]	new[191]	_	_
26-2	3893-3895	of	abstract[191]	new[191]	_	_
26-3	3896-3899	the	abstract[191]|place[192]	new[191]|giv[192]	ana	26-12[0_192]
26-4	3900-3907	pathway	abstract[191]|place[192]	new[191]|giv[192]	_	_
26-5	3908-3913	leads	_	_	_	_
26-6	3914-3916	to	_	_	_	_
26-7	3917-3920	the	event[193]	new[193]	_	_
26-8	3921-3934	stabilization	event[193]	new[193]	_	_
26-9	3935-3937	of	event[193]	new[193]	_	_
26-10	3938-3947	β-catenin	event[193]|abstract	new[193]|giv	coref	31-9[241_0]
26-11	3948-3951	and	_	_	_	_
26-12	3952-3955	its	place|abstract[196]	giv|new[196]	ana|ana	26-22|26-22
26-13	3956-3968	accumulation	abstract[196]	new[196]	_	_
26-14	3969-3975	within	abstract[196]	new[196]	_	_
26-15	3976-3979	the	abstract[196]|place[197]	new[196]|new[197]	_	_
26-16	3980-3987	cytosol	abstract[196]|place[197]	new[196]|new[197]	_	_
26-17	3988-3991	and	abstract[196]	new[196]	_	_
26-18	3992-3995	the	abstract[196]|place[198]	new[196]|new[198]	_	_
26-19	3996-4003	nucleus	abstract[196]|place[198]	new[196]|new[198]	_	_
26-20	4004-4005	,	_	_	_	_
26-21	4006-4011	where	_	_	_	_
26-22	4012-4014	it	place	giv	coref	27-13[210_0]
26-23	4015-4024	interacts	_	_	_	_
26-24	4025-4029	with	_	_	_	_
26-25	4030-4036	T-cell	abstract[200]	giv[200]	appos	26-30[0_200]
26-26	4037-4052	factor/lymphoid	abstract[200]	giv[200]	_	_
26-27	4053-4069	enhancer-binding	abstract[200]	giv[200]	_	_
26-28	4070-4076	factor	abstract[200]	giv[200]	_	_
26-29	4077-4078	(	_	_	_	_
26-30	4079-4086	TCF/LEF	abstract	giv	_	_
26-31	4087-4088	)	_	_	_	_
26-32	4089-4102	transcription	abstract|abstract[203]	new|giv[203]	coref|coref	26-37[204_0]|26-37[204_0]
26-33	4103-4110	factors	abstract[203]	giv[203]	_	_
26-34	4111-4114	and	_	_	_	_
26-35	4115-4122	thereby	_	_	_	_
26-36	4123-4132	regulates	_	_	_	_
26-37	4133-4146	transcription	abstract[204]	giv[204]	coref	32-9[244_204]
26-38	4147-4149	of	abstract[204]	giv[204]	_	_
26-39	4150-4158	multiple	abstract[204]|abstract[205]	giv[204]|new[205]	coref	32-26[251_205]
26-40	4159-4165	target	abstract[204]|abstract[205]	giv[204]|new[205]	_	_
26-41	4166-4171	genes	abstract[204]|abstract[205]	giv[204]|new[205]	_	_
26-42	4172-4173	.	_	_	_	_

#Text=During recent years , a multitude of other crosstalks and co-operations affecting the pathway have been identified .
27-1	4174-4180	During	_	_	_	_
27-2	4181-4187	recent	time[206]	new[206]	_	_
27-3	4188-4193	years	time[206]	new[206]	_	_
27-4	4194-4195	,	_	_	_	_
27-5	4196-4197	a	abstract[207]	new[207]	_	_
27-6	4198-4207	multitude	abstract[207]	new[207]	_	_
27-7	4208-4210	of	abstract[207]	new[207]	_	_
27-8	4211-4216	other	abstract[207]|abstract[208]	new[207]|new[208]	_	_
27-9	4217-4227	crosstalks	abstract[207]|abstract[208]	new[207]|new[208]	_	_
27-10	4228-4231	and	abstract[207]	new[207]	_	_
27-11	4232-4245	co-operations	abstract[207]|abstract	new[207]|new	_	_
27-12	4246-4255	affecting	_	_	_	_
27-13	4256-4259	the	place[210]	giv[210]	_	_
27-14	4260-4267	pathway	place[210]	giv[210]	_	_
27-15	4268-4272	have	_	_	_	_
27-16	4273-4277	been	_	_	_	_
27-17	4278-4288	identified	_	_	_	_
27-18	4289-4290	.	_	_	_	_

#Text=Interestingly , variants of the TCF-4 ( TCF7L2 ) gene have been associated with increased risk of type 2 diabetes .
28-1	4291-4304	Interestingly	_	_	_	_
28-2	4305-4306	,	_	_	_	_
28-3	4307-4315	variants	abstract[211]	new[211]	_	_
28-4	4316-4318	of	abstract[211]	new[211]	_	_
28-5	4319-4322	the	abstract[211]|abstract[212]	new[211]|new[212]	appos	28-8[0_212]
28-6	4323-4328	TCF-4	abstract[211]|abstract[212]	new[211]|new[212]	_	_
28-7	4329-4330	(	abstract[211]	new[211]	_	_
28-8	4331-4337	TCF7L2	abstract[211]|abstract	new[211]|giv	_	_
28-9	4338-4339	)	abstract[211]	new[211]	_	_
28-10	4340-4344	gene	abstract[211]|abstract	new[211]|new	coref	32-19
28-11	4345-4349	have	_	_	_	_
28-12	4350-4354	been	_	_	_	_
28-13	4355-4365	associated	_	_	_	_
28-14	4366-4370	with	_	_	_	_
28-15	4371-4380	increased	abstract[215]	new[215]	_	_
28-16	4381-4385	risk	abstract[215]	new[215]	_	_
28-17	4386-4388	of	abstract[215]	new[215]	_	_
28-18	4389-4393	type	abstract[215]|abstract[216]	new[215]|new[216]	_	_
28-19	4394-4395	2	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
28-20	4396-4404	diabetes	abstract[215]|abstract[216]|abstract[217]	new[215]|new[216]|new[217]	_	_
28-21	4405-4406	.	_	_	_	_

#Text=Based on that knowledge , we hypothesized that Wnt ligands as secreted , cysteine-rich proteins are susceptible to α-DC-mediated modifications and that glycation might modulate their signaling activities .
29-1	4407-4412	Based	_	_	_	_
29-2	4413-4415	on	_	_	_	_
29-3	4416-4420	that	abstract[218]	new[218]	_	_
29-4	4421-4430	knowledge	abstract[218]	new[218]	_	_
29-5	4431-4432	,	_	_	_	_
29-6	4433-4435	we	person	acc	ana	30-5
29-7	4436-4448	hypothesized	_	_	_	_
29-8	4449-4453	that	_	_	_	_
29-9	4454-4457	Wnt	abstract|substance[221]	giv|new[221]	coref|coref	32-27|32-27
29-10	4458-4465	ligands	substance[221]	new[221]	_	_
29-11	4466-4468	as	_	_	_	_
29-12	4469-4477	secreted	_	_	_	_
29-13	4478-4479	,	_	_	_	_
29-14	4480-4493	cysteine-rich	substance[222]	giv[222]	ana	29-26[0_222]
29-15	4494-4502	proteins	substance[222]	giv[222]	_	_
29-16	4503-4506	are	_	_	_	_
29-17	4507-4518	susceptible	_	_	_	_
29-18	4519-4521	to	_	_	_	_
29-19	4522-4535	α-DC-mediated	abstract[223]	giv[223]	_	_
29-20	4536-4549	modifications	abstract[223]	giv[223]	_	_
29-21	4550-4553	and	_	_	_	_
29-22	4554-4558	that	_	_	_	_
29-23	4559-4568	glycation	substance	giv	_	_
29-24	4569-4574	might	_	_	_	_
29-25	4575-4583	modulate	_	_	_	_
29-26	4584-4589	their	substance|abstract[227]	giv|new[227]	_	_
29-27	4590-4599	signaling	abstract|abstract[227]	giv|new[227]	_	_
29-28	4600-4610	activities	abstract[227]	new[227]	_	_
29-29	4611-4612	.	_	_	_	_

#Text=For this study , we decided to use Wnt3a as a proof of principle to study effects of GO-treatment on Wnt3a conditioned medium ( Wnt3a CM ) .
30-1	4613-4616	For	_	_	_	_
30-2	4617-4621	this	abstract[228]	new[228]	_	_
30-3	4622-4627	study	abstract[228]	new[228]	_	_
30-4	4628-4629	,	_	_	_	_
30-5	4630-4632	we	person	giv	ana	31-1
30-6	4633-4640	decided	_	_	_	_
30-7	4641-4643	to	_	_	_	_
30-8	4644-4647	use	_	_	_	_
30-9	4648-4653	Wnt3a	organization	new	coref	30-21
30-10	4654-4656	as	_	_	_	_
30-11	4657-4658	a	_	_	_	_
30-12	4659-4664	proof	_	_	_	_
30-13	4665-4667	of	_	_	_	_
30-14	4668-4677	principle	abstract	new	_	_
30-15	4678-4680	to	_	_	_	_
30-16	4681-4686	study	_	_	_	_
30-17	4687-4694	effects	abstract[232]	giv[232]	_	_
30-18	4695-4697	of	abstract[232]	giv[232]	_	_
30-19	4698-4710	GO-treatment	abstract[232]|object	giv[232]|new	_	_
30-20	4711-4713	on	_	_	_	_
30-21	4714-4719	Wnt3a	abstract|object[235]	giv|new[235]	coref|appos|coref|appos	30-25|30-25[237_235]|30-25|30-25[237_235]
30-22	4720-4731	conditioned	object[235]	new[235]	_	_
30-23	4732-4738	medium	object[235]	new[235]	_	_
30-24	4739-4740	(	_	_	_	_
30-25	4741-4746	Wnt3a	abstract|object[237]	giv|giv[237]	_	_
30-26	4747-4749	CM	object[237]	giv[237]	_	_
30-27	4750-4751	)	_	_	_	_
30-28	4752-4753	.	_	_	_	_

#Text=We observed that the ratio of phospho-β-catenin to total β-catenin increased .
31-1	4754-4756	We	person	giv	_	_
31-2	4757-4765	observed	_	_	_	_
31-3	4766-4770	that	_	_	_	_
31-4	4771-4774	the	quantity[239]	new[239]	_	_
31-5	4775-4780	ratio	quantity[239]	new[239]	_	_
31-6	4781-4783	of	quantity[239]	new[239]	_	_
31-7	4784-4801	phospho-β-catenin	quantity[239]|substance	new[239]|new	_	_
31-8	4802-4804	to	_	_	_	_
31-9	4805-4810	total	abstract[241]	giv[241]	_	_
31-10	4811-4820	β-catenin	abstract[241]	giv[241]	_	_
31-11	4821-4830	increased	_	_	_	_
31-12	4831-4832	.	_	_	_	_

#Text=As a further consequence , Wnt3a-induced activation of the β-catenin/TCF transcription complex was reduced as shown by reporter gene assays and by decreased expression of endogenous Wnt target genes .
32-1	4833-4835	As	_	_	_	_
32-2	4836-4837	a	_	_	_	_
32-3	4838-4845	further	_	_	_	_
32-4	4846-4857	consequence	_	_	_	_
32-5	4858-4859	,	_	_	_	_
32-6	4860-4873	Wnt3a-induced	abstract[242]	new[242]	_	_
32-7	4874-4884	activation	abstract[242]	new[242]	_	_
32-8	4885-4887	of	abstract[242]	new[242]	_	_
32-9	4888-4891	the	abstract[242]|abstract[244]	new[242]|giv[244]	_	_
32-10	4892-4905	β-catenin/TCF	abstract[242]|abstract|abstract[244]	new[242]|new|giv[244]	_	_
32-11	4906-4919	transcription	abstract[242]|abstract[244]	new[242]|giv[244]	_	_
32-12	4920-4927	complex	abstract[242]|abstract[244]	new[242]|giv[244]	_	_
32-13	4928-4931	was	_	_	_	_
32-14	4932-4939	reduced	_	_	_	_
32-15	4940-4942	as	_	_	_	_
32-16	4943-4948	shown	_	_	_	_
32-17	4949-4951	by	_	_	_	_
32-18	4952-4960	reporter	person|abstract[247]	new|new[247]	_	_
32-19	4961-4965	gene	abstract|abstract[247]	giv|new[247]	_	_
32-20	4966-4972	assays	abstract[247]	new[247]	_	_
32-21	4973-4976	and	_	_	_	_
32-22	4977-4979	by	_	_	_	_
32-23	4980-4989	decreased	abstract[248]	new[248]	_	_
32-24	4990-5000	expression	abstract[248]	new[248]	_	_
32-25	5001-5003	of	abstract[248]	new[248]	_	_
32-26	5004-5014	endogenous	abstract[248]|abstract[251]	new[248]|giv[251]	_	_
32-27	5015-5018	Wnt	abstract[248]|abstract|abstract[251]	new[248]|giv|giv[251]	_	_
32-28	5019-5025	target	abstract[248]|abstract|abstract[251]	new[248]|new|giv[251]	_	_
32-29	5026-5031	genes	abstract[248]|abstract[251]	new[248]|giv[251]	_	_
32-30	5032-5033	.	_	_	_	_
